Top

Published in:

01-10-2010 | Invited Commentary

Estrogen deficiency and bone loss in women with breast cancer

Author: Charles L. Shapiro

Published in: Breast Cancer Research and Treatment | Issue 3/2010

Excerpt

All women will lose bone as a consequence of normal aging and menopause-mediated bone loss due to the estrogen deficiency. However, not all women will develop osteoporosis. The development of osteoporosis can be thought of as an equation [1]: on one side of the equation peak bone mass usually attained by about age 30; on the other side is ongoing bone loss due to normal aging, menopausal-related bone loss, and genetic determinants such as family history, race, and low body mass index, as well as exposures or conditions that are potentially modifiable (i.e., current cigarette smoking, alcohol intake greater than two drinks per day, and chronic glucocorticoid therapy) [2, 3]. Taking these factors into account, each woman will have a peak bone mass and a unique set of risk factors for bone loss that determines whether she will experience a non-traumatic fracture or osteoporosis. In postmenopausal women with breast cancer, the relative risks of osteoporotic fractures are higher than women without history of breast cancer [4]. …

Ramaswamy B, Shapiro CL (2003) Osteopenia and osteoporosis in women with breast cancer. Semin Oncol 30(6):763–775CrossRefPubMed

Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359(9321):1929–1936CrossRefPubMed

Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19(4):385–397CrossRefPubMed

Chen Z, Maricic M, Aragaki AK, Mouton C, Arendell L, Lopez AM, Bassford T, Chlebowski RT (2009) Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women’s Health Initiative. Osteoporos Int 20(4):527–536CrossRefPubMed

Imai Y, Kondoh S, Kouzmenko A, Kato S (2010) Minireview: osteoprotective action of estrogens is mediated by osteoclastic estrogen receptor-alpha. Mol Endocrinol 24(5):877–885CrossRefPubMed

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kassmann H, Piswanger-Solkner JC, Seifert M, Ploner F, Menzel C, Dubsky P et al (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9(9):840–849CrossRefPubMed

Pant S, Shapiro CL (2008) Aromatase inhibitor-associated bone loss: clinical considerations. Drugs 68(18):2591–2600CrossRefPubMed

Molina JR, Barton DL, Loprinzi CL (2005) Chemotherapy-induced ovarian failure: manifestations and management. Drug Saf 28(5):401–416CrossRefPubMed

Shapiro CL, Manola J, Leboff M (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19(14):3306–3311PubMed

10.

Davison KS, Siminoski K, Adachi JD, Hanley DA, Goltzman D, Hodsman AB, Josse R, Kaiser S, Olszynski WP, Papaioannou A et al (2006) Bone strength: the whole is greater than the sum of its parts. Semin Arthritis Rheum 36(1):22–31CrossRefPubMed

11.

Felsenberg D, Boonen S (2005) The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 27(1):1–11CrossRefPubMed

12.

Hadjidakis DJ, Androulakis II (2006) Bone Remodeling. Ann N Y Acad Sci 1092(1):385–396CrossRefPubMed

13.

Manolagas SC, Jilka RL (1995) Bone marrow, cytokines, and bone remodeling emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332(5):305–311CrossRefPubMed

14.

Kearns AE, Khosla S, Kostenuik PJ (2008) Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29(2):155–192CrossRefPubMed

15.

Boyce BF, Xing L (2007) The RANKL/RANK/OPG pathway. Curr Osteoporos Rep 5(3):98–104CrossRefPubMed

16.

Kostenuik PJ (2005) Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5(6):618–625CrossRefPubMed

17.

Manolagas SC, Kousteni S, Jilka RL (2002) Sex steroids and bone. Recent Prog Horm Res 57:385–409CrossRefPubMed

18.

Weitzmann MN, Pacifici R (2006) Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 116(5):1186–1194CrossRefPubMed

19.

Imai Y, Youn M-Y, Kondoh S, Nakamura T, Kouzmenko A, Matsumoto T, Takada I, Takaoka K, Kato S (2009) Estrogens maintain bone mass by regulating expression of genes controlling function and life span in mature osteoclasts. Ann N Y Acad Sci 1173(S1):E31–E39CrossRefPubMed

20.

Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M (2008) Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 27(3):535–545CrossRefPubMed

21.

Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y et al (2007) Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130(5):811–823CrossRefPubMed

22.

Weitzmann MN, Pacifici R (2005) Role of the immune system in postmenopausal bone loss. Curr Osteoporos Rep 3(3):92–97CrossRefPubMed

23.

Weitzmann MN, Pacifici R (2007) T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis. Ann N Y Acad Sci 1116:360–375CrossRefPubMed

24.

Zallone A (2006) Direct and indirect estrogen actions on osteoblasts and osteoclasts. Ann N Y Acad Sci 1068:173–179CrossRefPubMed

25.

Weitzmann MN, Pacifici R (2005) The role of T lymphocytes in bone metabolism. Immunol Rev 208:154–168CrossRefPubMed

26.

Lea CK, Flanagan AM (1999) Ovarian androgens protect against bone loss in rats made oestrogen deficient by treatment with ICI 182, 780. J Endocrinol 160(1):111–117CrossRefPubMed

27.

Fogelman I, Blake GM, Blamey R, Palmer M, Sauerbrei W, Schumacher M, Serin D, Stewart A, Wilpshaar W (2003) Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 14(12):1001–1006CrossRefPubMed

28.

Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I (1997) Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 15(4):1341–1347PubMed

29.

Crandall C, Petersen L, Ganz PA, Greendale GA (2004) Bone mineral density and adjuvant therapy in breast cancer survivors. Breast Cancer Res Treat 88(3):257–261CrossRefPubMed

30.

Greep NC, Giuliano AE, Hansen NM, Taketani T, Wang HJ, Singer FR (2003) The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. Am J Med 114(8):653–659CrossRefPubMed

31.

Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N (1999) Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17(8):2365–2370PubMed

32.

Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA (2006) The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 21(10):2583–2592CrossRefPubMed

33.

Shapiro CL, Phillips G, Van Poznak CH, Jackson R, Leboff MS, Woodard S, Lemeshow S (2005) Baseline bone mineral density of the total lumbar spine may predict for chemotherapy-induced ovarian failure. Breast Cancer Res Treat 90(1):41–46CrossRefPubMed

34.

Chen Z, Arendell L, Aickin M, Cauley J, Lewis CE, Chlebowski R (2008) Hip bone density predicts breast cancer risk independently of Gail score: results from the Women’s Health Initiative. Cancer 113(5):907–915CrossRefPubMed

35.

Termine JD, Wong M (1998) Post-menopausal women and osteoporosis: available choices for maintenance of skeletal health. Maturitas 30(3):241–245CrossRefPubMed

36.

Shapiro CL, Halabi S, Gibson G et al (2008) Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): first results from CALGB trial 79809. J Clin Onc 26 (May 20 Suppl; abstract 512)

37.

Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S et al (2009) NCCN task force report: bone health in cancer care. J Natl Compr Cancer Netw 7(Suppl 3):S1–S32 (quiz S33–S35)

Title: Estrogen deficiency and bone loss in women with breast cancer
Author: Charles L. Shapiro
Publication date: 01-10-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-1099-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2010

Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine)

Mouse mammary tumor-like virus and human breast cancer

The role of RACK1 as an independent prognostic indicator in human breast cancer

Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases

Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer